Nutra Pharma Completes Patient Crossover in AMN Trial
Posted on: Tuesday, 18 December 2007, 15:00 CST
Nutra Pharma has reported that its drug discovery arm, ReceptoPharm, has successfully completed its six-month patient crossover in the Phase IIb/IIIa clinical trial for the treatment of adrenomyeloneuropathy.
The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo. RPI-78M is ReceptoPharm's lead drug candidate for the treatment of neurological and autoimmune disorders.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy).
Paul Reid, CEO of ReceptoPharm, said: "This is an important milestone in our clinical development process, as successful completion of this crossover acts as an early indication that our trial is running smoothly."
Source: Datamonitor
Related Articles
- Nutra Pharma's Subsidiary Renews Collaborative Agreement With CDC
- Nutra Pharma Announces Successful Completion of 6-Month Patient Crossover in AMN Clinical Trial
- Nutra Pharma Announces Successful Enrollment in ReceptoPharm Adrenomyeloneuropathy (AMN) Study
- Nutra Pharma Announces ReceptoPharm Patent for a Method of Treating Multiple Sclerosis
- ReceptoPharm Begins Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- Nutra Pharma Announces ReceptoPharm to Present at the International Conference on Neurotoxins
- Nutra Pharma Announces ReceptoPharm to Be a Featured Speaker at the 11th Annual Immunobiology Symposium
- Nutra Pharma Reports Preclinical Results of RPI-78M in Multiple Sclerosis to Be Presented at Scientific Meeting
- Nutra Pharma Reports Final Results for ReceptoPharm's RPI-78M in Multiple Sclerosis Animal Model
 |
 |
User Comments (0)
RSS Feeds